Skip to main content
Top
Published in: AIDS and Behavior 7/2016

01-07-2016 | Original Paper

Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population

Authors: Helena A. Kwakwa, Sophia Bessias, Donielle Sturgis, Natasha Mvula, Rahab Wahome, Catelyn Coyle, Timothy P. Flanigan

Published in: AIDS and Behavior | Issue 7/2016

Login to get access

Abstract

A majority of US studies on attitudes toward PrEP focus on men who have sex with men with little representation of African Americans. This cross-sectional study seeks to determine openness to PrEP, and examine motivations for openness among Philadelphia residents. Patients undergoing HIV rapid testing between May 2012 and December 2014 in a public setting were administered a survey. Questions included openness to PrEP and reasons for openness to PrEP. Multivariate logistic regression models were used to investigate associations between openness and potential predictors. Analyses were conducted using R version 3.2.4 and the epitools and car packages. Of 5606 respondents, over 90 % were African American. Men were more likely to express openness (61.4 % of men, 54.8 % of women, p < 0.0001). Predictors of openness were younger age, black race, higher perceived risk for HIV by patient or as assessed by Tester, intermittent /no condom use, greater number of partners in 12 months and previous HIV testing. The main reason for openness was fear of HIV, and for disinterest was lack of recognition of risk. Understanding openness to PrEP, and reasons for openness to or disinterest in PrEP are critical to determining the best approaches to facilitate engagement in PrEP care by communities and persons at elevated risk for HIV acquisition. Further study is needed on how best to manage disinterest in PrEP by those at high risk for HIV, and how openness to PrEP translates into concrete steps to take PrEP.
Literature
1.
go back to reference Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRefPubMedPubMedCentral
2.
go back to reference Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90.CrossRef Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet. 2013;381(9883):2083–90.CrossRef
3.
go back to reference Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.CrossRefPubMedPubMedCentral
4.
go back to reference Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, TDF2 Study Group, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, TDF2 Study Group, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
5.
go back to reference Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–60.CrossRefPubMed Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of pre-exposure prophylaxis for HIV-1 prevention among high risk heterosexuals: subgroup analyses from a randomized trial. AIDS. 2013;27(13):2155–60.CrossRefPubMed
6.
go back to reference Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.CrossRefPubMedPubMedCentral Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.CrossRefPubMedPubMedCentral
8.
go back to reference Rawlings K, Mera R, Pechonkina A, Rooney JF, Peschel T, Cheng A, et al. Status of Truvada (TVD) for HIV pre-esposure prophylaxis in the United States: an early drug utilization analysis. 53rd interscience conference on antimicrobial agents and chemotherapy (ICAAC 2013). Denver, Colorado, September 10–13, 2013. Rawlings K, Mera R, Pechonkina A, Rooney JF, Peschel T, Cheng A, et al. Status of Truvada (TVD) for HIV pre-esposure prophylaxis in the United States: an early drug utilization analysis. 53rd interscience conference on antimicrobial agents and chemotherapy (ICAAC 2013). Denver, Colorado, September 10–13, 2013.
9.
go back to reference Flash C, Landovitz R, Giler RM, Ng L, Magnuson D, Bush S, et al. Two years of Truvada for preexposure prophylaxis utilization in the US. J Int AIDS Soc 2014;17(Suppl 3):19730. Flash C, Landovitz R, Giler RM, Ng L, Magnuson D, Bush S, et al. Two years of Truvada for preexposure prophylaxis utilization in the US. J Int AIDS Soc 2014;17(Suppl 3):19730.
10.
go back to reference Bush S, Ng L, Magnuson D, et al. Significant uptake of Truvada for pre-exposure prophylaxis (PrEP) utilization in the US in late 2014-1Q2015. 10th international conference on HIV treatment and prevention adherence 2015; Miami, Florida, June 28–30, 2015. Bush S, Ng L, Magnuson D, et al. Significant uptake of Truvada for pre-exposure prophylaxis (PrEP) utilization in the US in late 2014-1Q2015. 10th international conference on HIV treatment and prevention adherence 2015; Miami, Florida, June 28–30, 2015.
11.
go back to reference Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnosis of HIV Infection and AIDS in the United States and Dependent Areas, 2013: Vol. 25. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnosis of HIV Infection and AIDS in the United States and Dependent Areas, 2013: Vol. 25.
12.
go back to reference Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefPubMed Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefPubMed
13.
go back to reference Eisingerich AB, Wheelock A, Gomez GB, Gernett GP, Dybul R, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238.CrossRefPubMedPubMedCentral Eisingerich AB, Wheelock A, Gomez GB, Gernett GP, Dybul R, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238.CrossRefPubMedPubMedCentral
14.
go back to reference Toledo L, McLellan-Lemal E, Henderson FL, Kebaabetswe PM. Knowledge, attitudes, and experiences of HIV pre-exposure prophylaxis (PrEP) trial participants in Botswana. World J AIDS. 2015;5(01):10.CrossRefPubMedPubMedCentral Toledo L, McLellan-Lemal E, Henderson FL, Kebaabetswe PM. Knowledge, attitudes, and experiences of HIV pre-exposure prophylaxis (PrEP) trial participants in Botswana. World J AIDS. 2015;5(01):10.CrossRefPubMedPubMedCentral
15.
go back to reference Koester K, Amico KR, Liu A, Mcmahon V, Hosek S, Mayer K, et al. Sex on PrEP:qualitative findings from the iPrex Open Lable Extension (iPrex OLE) in the United States. Twentieth international AIDS conference. Melbourne, Australia, July 20–25, 2014. Abstract TUAC0102. Koester K, Amico KR, Liu A, Mcmahon V, Hosek S, Mayer K, et al. Sex on PrEP:qualitative findings from the iPrex Open Lable Extension (iPrex OLE) in the United States. Twentieth international AIDS conference. Melbourne, Australia, July 20–25, 2014. Abstract TUAC0102.
16.
go back to reference Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed
17.
go back to reference Lorente N, Fugin L, Carrieri MP, Andreo C, Le Gall JM, Cook E, et al. Acceptability of “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care. 2012;24(4):468–77.PubMed Lorente N, Fugin L, Carrieri MP, Andreo C, Le Gall JM, Cook E, et al. Acceptability of “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care. 2012;24(4):468–77.PubMed
18.
go back to reference Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDs. 2010;24(11):689–91.CrossRefPubMed Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDs. 2010;24(11):689–91.CrossRefPubMed
19.
go back to reference Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Pre-exposure antiretroviral prophylaxis (PrEP) attitudes in high risk Boston area MSM: limited knowledge and experience, but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77.CrossRefPubMedPubMedCentral Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Pre-exposure antiretroviral prophylaxis (PrEP) attitudes in high risk Boston area MSM: limited knowledge and experience, but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77.CrossRefPubMedPubMedCentral
20.
go back to reference Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLos ONE. 2012;7(3):e33119.CrossRefPubMedPubMedCentral Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLos ONE. 2012;7(3):e33119.CrossRefPubMedPubMedCentral
21.
go back to reference Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Wienberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRefPubMedPubMedCentral Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Wienberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRefPubMedPubMedCentral
22.
go back to reference Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV serodiscordant male relationships. AIDS Care. 2011;23(9):1136–45.CrossRefPubMedPubMedCentral Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV serodiscordant male relationships. AIDS Care. 2011;23(9):1136–45.CrossRefPubMedPubMedCentral
23.
go back to reference Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.CrossRefPubMedPubMedCentral Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.CrossRefPubMedPubMedCentral
24.
go back to reference Gamarel KE, Golub SA. Intimacy motivations and pre-exposure prophylaxis (PrEP) adoption intentions among HIV-negative men who have sex with men (MSM) in romantic relationships. Ann Behav Med. 2015;49:177–86.CrossRefPubMedPubMedCentral Gamarel KE, Golub SA. Intimacy motivations and pre-exposure prophylaxis (PrEP) adoption intentions among HIV-negative men who have sex with men (MSM) in romantic relationships. Ann Behav Med. 2015;49:177–86.CrossRefPubMedPubMedCentral
25.
go back to reference Hoff CC, Chakravarty D, Bircher AE, Campbell CK, Grisham K, Neilands TB, et al. Attitudes towards PrEP and anticipated condom use among concordant HIV-negative and HIV-discordant male couples. AIDS Patient Care STDs. 2015;29(7):408–17.CrossRefPubMed Hoff CC, Chakravarty D, Bircher AE, Campbell CK, Grisham K, Neilands TB, et al. Attitudes towards PrEP and anticipated condom use among concordant HIV-negative and HIV-discordant male couples. AIDS Patient Care STDs. 2015;29(7):408–17.CrossRefPubMed
26.
go back to reference Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408–21.CrossRefPubMed Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408–21.CrossRefPubMed
27.
go back to reference Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDs. 2011;25(6):365–70.CrossRefPubMed Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDs. 2011;25(6):365–70.CrossRefPubMed
30.
go back to reference Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18(2):195–216.CrossRefPubMed Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18(2):195–216.CrossRefPubMed
31.
go back to reference Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs. 2015;29(2):102–10.CrossRefPubMedPubMedCentral Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs. 2015;29(2):102–10.CrossRefPubMedPubMedCentral
32.
go back to reference Flash CA, Stone VE, Mitty JA, Mimiaga MJ, Hall KT, Krakower D, et al. Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDs. 2014;28(12):635–42.CrossRefPubMedPubMedCentral Flash CA, Stone VE, Mitty JA, Mimiaga MJ, Hall KT, Krakower D, et al. Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDs. 2014;28(12):635–42.CrossRefPubMedPubMedCentral
33.
go back to reference Wingood GM, Dunkle K, Camp C, Patel S, Painter JE, Rubtsova A, et al. Racial differences and correlates of potential adoption of pre-exposure prophylaxis (PrEP): results of a national survey. J Acquir Immune Defic Syndr. 2013;63(01):S95–101.CrossRefPubMedPubMedCentral Wingood GM, Dunkle K, Camp C, Patel S, Painter JE, Rubtsova A, et al. Racial differences and correlates of potential adoption of pre-exposure prophylaxis (PrEP): results of a national survey. J Acquir Immune Defic Syndr. 2013;63(01):S95–101.CrossRefPubMedPubMedCentral
35.
36.
go back to reference Denning P, DiNenno E. Communities in crisis: is there a generalized HIV epidemic in impoverished urban areas of the United States. XVIII international AIDS conference 2010. Vienna. Denning P, DiNenno E. Communities in crisis: is there a generalized HIV epidemic in impoverished urban areas of the United States. XVIII international AIDS conference 2010. Vienna.
37.
go back to reference Kwakwa HA, Wahome R, Bessias S. HIV disparities in a US and foreign-bornn cohort in urban United States. J AIDS Clin Res. 2015;6:515. Kwakwa HA, Wahome R, Bessias S. HIV disparities in a US and foreign-bornn cohort in urban United States. J AIDS Clin Res. 2015;6:515.
38.
go back to reference AIDS Activities Coordinating Office (AACO) Surveillance Report 2014: HIV/AIDS in Philadelphia. City of Philadelphia Department of Public Health 2014. AIDS Activities Coordinating Office (AACO) Surveillance Report 2014: HIV/AIDS in Philadelphia. City of Philadelphia Department of Public Health 2014.
39.
go back to reference Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDs. 2012;26(4):222–33.PubMed Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDs. 2012;26(4):222–33.PubMed
40.
go back to reference Nunn A, Zaller N, Cornwall A, Mayer KH, Moore E, Dickman S, et al. Low perceived risk and high HIV prevalence among a predominantly African American population participating in Philadelphia’s rapid HIV testing program. AIDS Patient Care STDs. 2011;25(4):17.CrossRef Nunn A, Zaller N, Cornwall A, Mayer KH, Moore E, Dickman S, et al. Low perceived risk and high HIV prevalence among a predominantly African American population participating in Philadelphia’s rapid HIV testing program. AIDS Patient Care STDs. 2011;25(4):17.CrossRef
Metadata
Title
Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population
Authors
Helena A. Kwakwa
Sophia Bessias
Donielle Sturgis
Natasha Mvula
Rahab Wahome
Catelyn Coyle
Timothy P. Flanigan
Publication date
01-07-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1407-9

Other articles of this Issue 7/2016

AIDS and Behavior 7/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.